Agilent's mmr ihc panel pharmdx (dako omnis) receives european ivdr certification as a companion diagnostic test for colorectal cancer

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced that its mmr ihc panel pharmdx (dako omnis) has received class c companion diagnostic (cdx) certification under eu in vitro diagnostic regulation (ivdr)1 as a cdx test for colorectal cancer. mmr ihc panel pharmdx (dako omnis) is indicated as an aid to identify mismatch repair (mmr) deficient crc patients eligible for treatment with opdivo® (nivolumab) in combination with yervoy® (ipilimumab). mmr ihc panel.
A Ratings Summary
A Quant Ranking